Human Immunodeficiency Virus type 1 (HIV-1) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

 Human Immunodeficiency Virus type 1 (HIV-1) is a retrovirus that infects humans and is the primary cause of acquired immunodeficiency syndrome (AIDS). It belongs to the Lentivirus genus of the Retroviridae family. HIV-1 is one of the two major types of HIV, the other being HIV-2. HIV-1 is transmitted by exchanging body fluids, including blood, semen, vaginal fluids, rectal fluids, and breast milk. The most common transmission routes include unprotected sexual contact with an infected person, sharing needles or syringes with an infected person, and transmission from an infected mother to her child during childbirth or breastfeeding. Once the virus enters the body, it primarily targets and infects CD4+ T cells, a type of white blood cell crucial for the immune system's proper functioning. As the virus replicates, it progressively destroys these CD4+ T cells, weakening the immune system and making the person more susceptible to opportunistic infections and certain cancers. The course of HIV infection is divided into several stages:

1.       Acute HIV infection: This occurs within a few weeks after the initial infection and may cause flu-like symptoms such as headache, fever, sore throat, swollen lymph nodes, and rash.

2.       Clinical latency: After the initial stage, HIV remains in the body but may not cause noticeable symptoms for an extended period. However, the virus continues to replicate and damage the immune system during this time.

3.       Acquired Immunodeficiency Syndrome (AIDS): If HIV is left untreated, the immune system becomes severely damaged, and the person is diagnosed with AIDS. At this stage, the individual becomes highly susceptible to opportunistic infections and certain cancers.

HIV can be managed effectively with antiretroviral therapy (ART), a combination of medications that helps suppress viral replication and maintain a healthy immune system. While ART does not cure HIV, it allows people living with the virus to lead relatively healthy lives and significantly reduces the risk of transmitting it to others.

 

·       The estimated number of HIV infections in the USA was 12.6 per 100,000.

 

Thelansis’s “Human Immunodeficiency Virus type 1 (HIV-1) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Human Immunodeficiency Virus type 1 (HIV-1) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

 

KOLs insights of Human Immunodeficiency Virus type 1 (HIV-1) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Human Immunodeficiency Virus type 1 (HIV-1) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Human Immunodeficiency Virus type 1 (HIV-1) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Tags: Human Immunodeficiency Virus type 1 (HIV-1), Human Immunodeficiency Virus type 1 (HIV-1) market outlook, Human Immunodeficiency Virus type 1 (HIV-1) competitive landscape, Human Immunodeficiency Virus type 1 (HIV-1) market forecast, Thelansis, Primary market research, KOL insights, Competitive Intelligence (CI)